Identify the anti-apoptotic factor among the following:

Explanation

## Correct Answer: D. Bcl-2 Bcl-2 (B-cell lymphoma-2) is the prototypical **anti-apoptotic protein** that prevents programmed cell death by blocking mitochondrial outer membrane permeabilization (MOMP). It was first identified in B-cell lymphomas where chromosomal translocation t(14;18) leads to Bcl-2 overexpression, preventing normal apoptosis of malignant cells. Bcl-2 works by sequestering pro-apoptotic proteins (BAX, BAK) and inhibiting cytochrome c release from mitochondria, thereby blocking the intrinsic apoptotic pathway. In the mitochondrial pathway, Bcl-2 family proteins act as gatekeepers—anti-apoptotic members (Bcl-2, Bcl-xL, Mcl-1) oppose pro-apoptotic members (BAX, BAK, BIM). This balance determines cell fate. Overexpression of Bcl-2 is seen in various Indian malignancies including lymphomas and some carcinomas, making it a critical oncogene. The Bcl-2/BAX ratio is a key determinant of apoptotic susceptibility in cancer cells, and this principle is exploited therapeutically by drugs like venetoclax (a Bcl-2 inhibitor used in CLL). Understanding Bcl-2 function is essential for comprehending both normal cell homeostasis and cancer biology. ## Why the other options are wrong **A. P-53** — P-53 is a **pro-apoptotic tumor suppressor**, not anti-apoptotic. It activates apoptosis by transactivating pro-apoptotic genes (BAX, PUMA, NOXA) and repressing anti-apoptotic genes. P-53 is called the 'guardian of the genome' because it triggers apoptosis in response to DNA damage. Loss of P-53 (not overexpression) promotes cancer by preventing apoptosis of damaged cells. This is a common NBE trap—confusing tumor suppressors with oncogenes. **B. BAK** — BAK is a **pro-apoptotic protein** of the Bcl-2 family, not anti-apoptotic. It is a BAX-like effector that promotes mitochondrial outer membrane permeabilization and cytochrome c release, leading to caspase activation and apoptosis. BAK and BAX are functionally redundant executioners of the intrinsic apoptotic pathway. Overexpression of BAK would *increase* apoptosis, opposite to the question's requirement. **C. K-ras** — K-ras is an **oncogenic GTPase** involved in growth signaling (MAPK pathway), not directly in apoptosis regulation. While mutant K-ras promotes cell proliferation and can suppress apoptosis indirectly through survival signals, it is not classified as an anti-apoptotic factor in the canonical Bcl-2 family framework. K-ras mutations are common in Indian pancreatic and colorectal cancers but do not directly inhibit apoptosis like Bcl-2 does. ## High-Yield Facts - **Bcl-2** is the prototypical anti-apoptotic protein that prevents cytochrome c release and blocks the intrinsic apoptotic pathway. - **t(14;18) translocation** in B-cell lymphomas juxtaposes Bcl-2 to the immunoglobulin heavy chain promoter, causing Bcl-2 overexpression and lymphomagenesis. - **Bcl-2/BAX ratio** determines apoptotic susceptibility; high Bcl-2:BAX favors survival, low ratio favors apoptosis. - **P-53** is pro-apoptotic (activates BAX, PUMA, NOXA); **BAK** is pro-apoptotic (executes MOMP); only **Bcl-2** is anti-apoptotic. - **Venetoclax**, a Bcl-2 inhibitor, is used in CLL and AML by blocking Bcl-2's anti-apoptotic function, forcing cancer cells into apoptosis. ## Mnemonics **BAD vs. GOOD (Bcl-2 family mnemonic)** **BAD** = BAX, BAK, BIM, BID, PUMA, NOXA (pro-apoptotic). **GOOD** = Bcl-2, Bcl-xL, Mcl-1 (anti-apoptotic). When BAD wins, cell dies. When GOOD wins, cell survives. Use this to instantly classify any Bcl-2 family member. **Anti-apoptotic = Anti-death = Bcl-2** Only **Bcl-2** (and its homologs Bcl-xL, Mcl-1) block apoptosis. All others in this question either promote apoptosis (P-53, BAK) or are unrelated (K-ras). Bcl-2 = survival signal. ## NBE Trap NBE pairs Bcl-2 with lymphomas to test if students know that Bcl-2 *prevents* apoptosis (making it oncogenic), not that it causes cancer directly. Students may confuse P-53 (tumor suppressor) with Bcl-2 (oncogene) if they forget that P-53 *activates* apoptosis in response to DNA damage. ## Clinical Pearl In Indian lymphoma patients, Bcl-2 overexpression (detected by immunohistochemistry or flow cytometry) is a marker of poor prognosis because these cells evade apoptosis. Venetoclax, now available in India, directly targets Bcl-2 and has revolutionized CLL treatment by forcing apoptosis in these resistant cells. _Reference: Robbins Ch. 1 (Cell Injury & Death); Harrison Ch. 69 (Apoptosis & Necrosis)_